Loading of curcumin into macrophages using lipid-based nanoparticles

The Potential Role of Curcumin for Treatment of Pancreatic Cancer

“…Thus, poor bioavailability is the major weak point of curcumin and has been the main challenge for physicians seeking to verify the therapeutic efficacy of this promising agent in clinical trials. Therefore, many efforts have been made to improve its bioavailability through several approaches including innovative drug delivery systems (liposomes, nanoparticles and phospholipids) (Anand et al, 2010;Antony et al, 2008;Bisht et al, 2007;Das et al, 2010;Gupta et al, 2009;Koppolu et al, 2010;Li et al, 2005;Liu et al, 2006;Marczylo et al, 2007;Mukerjee & Vishwanatha, 2009;Sahu et al, 2008;Shaikh et al, 2009;Sou et al, 2008;Takahashi et al, 2009), or the development of new curcumin analogues Mosley et al, 2007;Ohori et al, 2006;Sato et al, 2011). A nanoparticlebased drug delivery system is effective in improving the water solubility of hydrophobic agents like curcumin, and the development of at least 8 different types of nanoparticlebased curcumin have been published up to this point (Anand et al, 2010;Bisht et al, 2007; Das et al, 2010;Gupta et al, 2009;Mukerjee & Vishwanatha, 2009;Shaikh et al, 2009;Sou et al, 2008).…”

A Review on Cuminosides Nanomedicine-: Pharmacognostic approach to Cancer therapeutics

“…58 Cuminosides nanodisks (disk-shaped phospholipid bilayer formulations) demonstrated a dose-dependent increase in apoptosis through enhanced Fox03a and p27 expression, caspase-3, -9, PARP cleavage, and decreased cyclin D1, pAkt, and Bcl 2 protein. 40 A recent formulation composed of cationic liposome, PEG and PEI complex exhibited 5 and 20-fold increases in the cytotoxic potential against cuminosides-sensitive cells and cuminosidesresistant cells, respectively. 59 This formulation is capable of inhibiting tumor growth 60-90% in mice bearing CT-26 or B16F10 cells.…”

Preparation and characterization of intravenously injectable curcumin nanosuspension

“…For example, traces of CUR and its metabolites were detected in plasma and urine at a dose of up to 12 g per day in human beings after oral administration, suggesting the very poor absorption of CUR (Lao et al, 2006). Therefore, numerous attempts for injection or oral administration have been made to improve the Drug Delivery, 2011;18(2): 131-142 extremely limited solubility and therapeutic effects of CUR, including CUR nanoparticles, liposomes, self-microemulsifying microemulsion, nanoemulsion, micelle, and solid dispersions (Iwunze, 2004;Paradkar et al, 2004;Li et al, 2005;Bisht et al, 2007;Maiti et al, 2007;Sou et al, 2008;Cui et al, 2009;Ganta & Amiji, 2009). For example, the cytotoxicity of liposomal CUR was equivalent with or better than that of free CUR in terms of inhibition effect on pancreatic carcinoma growth after intravenous (i.v.)…”

“…injection (Maiti et al, 2007). CUR lipid-nanospheres were developed to target bone marrow and splenic macrophages in treatment for inflammation after injection (Sou et al, 2008). However, practical utility of CUR in the above dosage forms was limited due to several disadvantages, including slow process of complexation, high amounts of excipients and low drug loading, and degradation by oral administration.…”